Dr. Oh on Targeted Treatment in Metastatic Castration-Resistant Prostate Cancer
February 8th 2020
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).